Synaptogenix Inc (SNPX)
4.76
-0.07
(-1.45%)
USD |
NASDAQ |
May 23, 12:24
Synaptogenix Shareholders Equity (Quarterly): 22.88M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 22.88M |
| December 31, 2023 | 25.58M |
| September 30, 2023 | 28.43M |
| June 30, 2023 | 26.91M |
| March 31, 2023 | 34.19M |
| December 31, 2022 | 35.41M |
| September 30, 2022 | 26.67M |
| June 30, 2022 | 28.95M |
| Date | Value |
|---|---|
| March 31, 2022 | 31.68M |
| December 31, 2021 | 33.53M |
| September 30, 2021 | 31.35M |
| June 30, 2021 | 32.19M |
| March 31, 2021 | 15.41M |
| December 31, 2020 | 5.138M |
| September 30, 2020 | 27.85M |
| December 31, 2019 | 17.42M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
5.138M
Minimum
Dec 2020
35.41M
Maximum
Dec 2022
26.47M
Average
28.14M
Median
Shareholders Equity (Quarterly) Benchmarks
| CEL-SCI Corp | 14.30M |
| AIM ImmunoTech Inc | 4.826M |
| IGC Pharma Inc | 9.053M |
| NovaBay Pharmaceuticals Inc | 0.16M |
| Protalix BioTherapeutics Inc | 29.79M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 29.40M |
| Total Liabilities (Quarterly) | 6.523M |